COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today announced the first use in Japan of its Spectranetics Laser Sheath (SLS® II) technology for removal of cardiac leads. The SLS II approval by the Ministry of Health, Labor and Welfare is one of just three medical device technologies chosen annually under a fast track review in Japan. This technology has been used in the United States and Europe for over a decade in over 45,000 successful procedures and is an important tool to manage lead-related issues that may arise in the roughly 4 million pacing and defibrillation leads implanted annually in patients worldwide.
